Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy

Abstract: Approximately 20% of diffuse large B-cell lymphoma have aberrations involving the programmed death ligands 1 and 2 (PD-L1/PD-L2) locus. This justifies the investigation of PD-1 checkpoint inhibitors in the frontline therapy setting in a bid to improve outcomes, especially in patients with...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Oluwatobi Odetola, Shuo Ma, Jane Winter, Barbara Pro, Ishan Roy, Ping Xie, Bin Zhang, Qing Chen, George P. Koulogeorgas, Xinlei Mi, Ruohui Chen, Yangruijue Ma, Xiaodan Tang, Robert Bayer, Robert Eisner, Valerie Nelson, Habib Shaikh, Dean Tsarwhas, Faisal Saghir, Parameswaran Venugopal, Leo I. Gordon, Reem Karmali
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-11-01
סדרה:	Blood Advances
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2473952925004355
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!